

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HUANG et al.

Continuation of Appln. No. 10/270,313

Confirmation No. Not Yet Assigned

Filed: December 16, 2003

For: METHOD FOR TREATMENT OF
TUMORS USING
NORDIHYDROGUAIARETIC
ACID DERIVATIVES

Art Unit: 1614

Examiner: James H. Reamer

Atty. Docket No.: 2240-199065

Customer No.:

26694

Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents that are listed on the attached PTO-1449 forms. All of the listed references are of record in parent Application No. 10/270,313 where copies may be obtained in accordance with customary PTO practice. Applicants request that these documents be considered and listed on the face of any patent granted in this application.

Respectfully submitted,

Date: 12/16/03

C. S. Hobbs

Ann S. Hobbs, Ph.D.

Registration No. 36,830

VENABLE

P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 344-4000

Telefax: (202) 344-8300

#509191v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2022. GPO 2017-088

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number 2240-199065

Complete if Known

Application Number	Continuation of Appln. 10/270,313
Filing Date	December 16, 2003
First Named Inventor	Ru Chih C. HUANG et al.
Group Art Unit	1614
Examiner Name	Mr. James H. Reamer

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
1	6,365,787			Huang et al.	04/2002	
2	5,663,209			Huang et al.	09/1997	
3	6,291,524			Huang et al.	09/2001	
4	6,214,874			Huang et al.	04/2001	
5	4,774,229			Jordan	09/1988	
6	5,276,060			Neiss et al.	01/1994	
7	6,071,949			Mulshine et al.	06/2000	
8	4,425,327			Moller et al.	01/1984	
9	4,880,637			Jordan	11/1989	
10	5,008,294			Neiss et al.	04/1991	
11	5,559,149			Clum et al.	09/1996	
12	5,827,898			Khandwala et al.	10/1998	
13	5,837,252			Sinnott et al.	11/1998	
14	5,965,616			Wang et al.	10/1999	
15	6,165,788			Bennett et al.	12/2000	
16	6,245,523			Altieri	01/2001	

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	2	Of	2	Application Number	Continuation of Appln. 10/270,313
				Filing Date	December 16, 2003
				First Named Inventor	Ru Chih C. HUANG et al.
				Group Art Unit	1614
				Examiner Name	Mr. James H. Reamer
				Attorney Docket Number	2240-199065
OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	17	Russell et al.; "Neoplasm inhibitors comprising metal salts and phenol derivatives"; CA: 111(3)17704R PATENT ABSTRACT			
	18	Rao et al.; "Regioselective cleavage of the methylenedioxy group: conversion of (-)-austrobailignan-5 to (-)-dihydroguaiaretic acid"; CA: 112(23)118499d JOURNAL ABSTRACT			
	19	Giza et al., "A self-inducing runaway--replication plasmid expression system utilizing the ROP protein," Gene 78:73-84 (1989).			
	20	Gnabre et al., "Isolation of anti-HIV-1 lignans from <i>Larrea tridentata</i> counter-current chromatography," J. Chromatography A, 719: 353-364 (1995).			
	21	C.W. Perry et al., "Synthesis of Lignans. I. Nordihydroguaiaretic Acid"; J. Org Chem. 37(26): 4371-4376 (1972).			
	22	Staal et al., "Antioxidants inhibit stimulation of HIV transcription," AIDS Research and Human Retroviruses, 9(4): 299-306 (1993).			
	23	Weislow et al., "New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS---Antiviral activity," J. National Cancer Inst. 81(1): 577-586 (1989).			
	24	Russell; "Compositions containing catecholic butanes and zinc for treating solid tumors"; CA: 110(12)101816r PATENT ABSTRACT			
	25	Chen et al., Antiviral Activities of Methylated Nordihydroguaiaretic Acids 2. Targeting Herpes Simplex Virus Replication by Mutation Insensitive Transcription Inhibitor Tetra-O-methyl-NDGA, Journal of Medicinal Chemistry, 1998, Vol. 41, No. 16, pp.301-3007			
	26	Gnabre et al., Characterization of Anti-HIV Lignans from <i>Larrea Tridentata</i> , Tetrahedron 1995, Vol. 51, No. 45, pp. 12203-12210			
	27	Gnabre et al., Inhibition of Human Immunodeficiency Virus Type 1 Transcription and Replication by DNA Sequence-S-selective Plant Lignans, Proc. Natl. Acad. Sci., USA, 1995, Vol. 92, pp. 11239-11243			
	28	Gisvold et al., Lignans from <i>Larrea Divaricata</i> , Journal of Pharmaceutical Sciences, 1994, Vol. 63, No. 12, pp. 1905-1907			
	29	Hwu et al., Antiviral Activities of Methylated Nordihydroguaiaretic Acids. 1. Synthesis Structure Identification and Inhibition of Tat-Regulated HIV Transactivation J. Med. Chem., 1998, Vol. 41, No. 16, pp. 2994-3000			
	30	Huang et al., Regulation of HIV Promotor Activities in Human Embryonal Carcinoma Cells, NTERA-2, Gene Regulation and AIDS, 1989, pp. 147-160			
	31	Li et al., Transcriptional Analysis of Human Survivin Gene Expression, Biochem. J. (1999), 344 pp. 305-311.			
	32	Connor et al., Regulation of Apoptosis Cell Division by p34cdc2 Phosphorylation of Survivin, PNAS, Nov. 21, 2000, Vol. 27, No. 24, pp. 13101-13107			
	33	Li et al., The Cancer Antiapoptosis Mouse Survivin Gene: Characterization of Locus and Transcriptional Requirements of Basal and Cell Cycle-Dependent Expression, Cancer Research 59, July 1, 1999, pp. 3134-3151			
Examiner Signature				Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.